RecruitingNCT04464122

Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)

Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN. REBORN Study

Sponsor

University of Roma La Sapienza

Enrollment

60 participants

Start Date

Sep 14, 2020

Study Type

OBSERVATIONAL

Conditions

Neuroendocrine Neoplasm Neuroendocrine Tumors Neuroendocrine Carcinoma Neuroendocrine Tumor Grade 1 Neuroendocrine Tumor Grade 2

Summary

This is a multicentre, controlled, observational prospective study on new biomarkers, as immune profiling, angiogenetic markers and circRNA from TEPs in the diagnosis and in the evaluation of treatment response in pulmonary and gastro-entero-pancreatic NENs.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Somatostatin analog; chemotherapy for people with neuroendocrine carcinoma, neuroendocrine neoplasm, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSomatostatin analog; chemotherapy

According to current ENETS guidelines, patients will be treated by somatostatin analogs or chemotherapy, recommended respectively as first line therapy in neuroendocrine tumours or neuroendocrine neoplasms.